Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cromolyn increases strength in exercised mdx mice

J A Granchelli1, D L Avosso, M S Hudecki

  • 1Department of Biological Sciences, SUNY at Buffalo, NY 14260-1300, USA.

Research Communications in Molecular Pathology and Pharmacology
|March 1, 1996
PubMed
Summary

Cromolyn treatment significantly improved strength in exercised mdx mice, suggesting potential for Duchenne muscular dystrophy therapy. Further research is needed to understand the observed increases in creatine kinase (CK) and mast cell tryptase activity.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regenerated mdx mouse skeletal muscle shows differential mRNA expression.

Journal of applied physiology (Bethesda, Md. : 1985)·2002
Same author

Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdx mice.

Muscle & nerve·2001
Same author

Pre-clinical screening of drugs using the mdx mouse.

Neuromuscular disorders : NMD·2000
Same author

Natriuretic peptides in fish physiology.

Comparative biochemistry and physiology. Part A, Molecular & integrative physiology·2000
Same author

Local synthesis of natriuretic peptides in the eel intestine.

Biochemical and biophysical research communications·1997
Same author

Duchenne-like myopathy in double-mutant mdx mice expressing exaggerated mast cell activity.

Journal of the neurological sciences·1995

Area of Science:

  • Pharmacology
  • Musculoskeletal Disorders
  • Immunology

Background:

  • Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by progressive muscle degeneration.
  • Exercise exacerbates muscle weakness in mdx mice, a common model for DMD.
  • Current treatments for DMD have limited efficacy, necessitating novel therapeutic approaches.

Purpose of the Study:

  • To evaluate the efficacy of cromolyn and compound 48/80 in improving muscle strength in exercised mdx mice.
  • To assess the impact of these pharmacologic agents on serum creatine kinase (CK) and mast cell tryptase levels.
  • To explore the potential of cromolyn-like compounds as a therapeutic strategy for Duchenne muscular dystrophy.

Main Methods:

  • MDX mice were treated with cromolyn, compound 48/80, prednisone, or vehicle from 2 weeks of age.

Related Experiment Videos

  • Treated mice underwent forced treadmill running at 4 weeks of age to induce muscle weakness.
  • Muscle strength was assessed weekly via a "pull-test" up to 6 weeks of age.
  • Serum CK and mast cell tryptase activities were measured from blood samples at 6 weeks.

    • Main Results:

    • Cromolyn treatment resulted in a significant increase in muscle strength in mdx mice (p < 0.05).
    • Compound 48/80 and prednisone did not show significant improvements in strength compared to vehicle controls.
    • While mast cell tryptase activity remained unchanged, CK activity was significantly elevated in the cromolyn group.
    • A combined analysis of tryptase and CK (Tryp x CK) showed significant differences in the cromolyn-treated group compared to all others.

    Conclusions:

    • Cromolyn demonstrates potential as a therapeutic agent for Duchenne muscular dystrophy.
    • The observed increase in CK activity with cromolyn warrants further investigation.
    • Cromolyn-like compounds may offer a novel treatment avenue for DMD, potentially by modulating mast cell activity or other pathways.